GlassScriptPhysician profile
Christy C Riddle
NPI 1992835565
$4,787.48
in general payments reported to CMS, 2019-2025
25 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $183 · 2021: $67.88 · 2022: $594 · 2023: $662 · 2024: $1,019 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,846 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,845.69 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,073.44 | 2019-2025 | |
| Lilly USA, LLC | $722.22 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $651.29 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $353.72 | 2022-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $335.45 | 2019-2025 | Ilumya, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $216.68 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $195.61 | 2019-2025 | Tremfya |
| Ucb, INC. | $155.50 | 2024-2025 | Bimzelx |
| Medimetriks Pharmaceuticals, INC. | $140.61 | 2019 | |
| Galderma Laboratories, L.P. | $130.33 | 2022-2025 | Nemluvio |
| Amgen INC. | $98.36 | 2020-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $97.96 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $87.29 | 2020 | |
| Novartis Pharmaceuticals Corporation | $79.14 | 2019-2021 | |
| Biofrontera INC. | $75.09 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71.89 | 2022-2024 | |
| Leo Pharma INC. | $71.82 | 2022-2023 | Adbry |
| Botanix Sb INC | $58.19 | 2025 | Sofdra |
| Incyte Corporation | $49.44 | 2022-2025 | Opzelura |
| Journey Medical Corporation | $31.80 | 2022-2025 | |
| Celgene Corporation | $24.69 | 2019 | |
| Verrica Pharmaceuticals INC. | $18.67 | 2024 | Ycanth |
| Almirall LLC | $18.05 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.24 | 2019 | |
| Dermavant Sciences, INC. | $14.00 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Riddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.